Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5926371 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK5926371 | EXPERIMENTAL | - |
| Part 1: Dose Escalation of GSK5926371 | EXPERIMENTAL | - |
| Part 2: Dose Division of GSK5926371 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5926371 | DRUG | GSK5926371 will be administered at different dose levels. |
Inclusion Criteria: * Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated, 1. Has measurable disease, 2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for th...
GSK5926371 is an investigational small molecule being studied for the treatment of B-cell driven autoimmune rheumatic diseases, including Systemic Lupus Erythematosus, and for relapsed or refractory B-cell Non-Hodgkin Lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
GSK5926371 is a small molecule designed to modulate B-cell driven pathways. It is being investigated for its potential to affect B-cell activity in autoimmune and oncologic conditions, though its specific molecular target has not been publicly disclosed.
GSK5926371 is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company is conducting Phase 1 clinical trials to evaluate the safety and clinical activity of this investigational drug.
GSK5926371 is in Phase 1 clinical development. It is currently being evaluated in two Phase 1 studies: one in participants with Systemic Lupus Erythematosus and another in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The drug remains investigational and has not received FDA approval.
GSK5926371 is being studied in two Phase 1 trials. NCT07371468 is recruiting participants with Systemic Lupus Erythematosus across multiple countries. NCT07607925 is a not-yet-recruiting study in adults with relapsed or refractory B-NHL in the United States, Canada, and Japan.
No alternative names for GSK5926371 have been disclosed. The drug is identified solely by its compound designation GSK5926371 in clinical trial registries and is not known to be marketed under any other brand name.